[go: up one dir, main page]

EA201690872A2 - Противовирусная терапия - Google Patents

Противовирусная терапия

Info

Publication number
EA201690872A2
EA201690872A2 EA201690872A EA201690872A EA201690872A2 EA 201690872 A2 EA201690872 A2 EA 201690872A2 EA 201690872 A EA201690872 A EA 201690872A EA 201690872 A EA201690872 A EA 201690872A EA 201690872 A2 EA201690872 A2 EA 201690872A2
Authority
EA
Eurasian Patent Office
Prior art keywords
combinations
viral therapy
aids
treating
hiv
Prior art date
Application number
EA201690872A
Other languages
English (en)
Other versions
EA201690872A3 (ru
EA032868B1 (ru
Inventor
Марк Ричард Андервуд
Original Assignee
Вайв Хелткер Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44319704&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201690872(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Вайв Хелткер Компани filed Critical Вайв Хелткер Компани
Publication of EA201690872A2 publication Critical patent/EA201690872A2/ru
Publication of EA201690872A3 publication Critical patent/EA201690872A3/ru
Publication of EA032868B1 publication Critical patent/EA032868B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Настоящее изобретение относится к комбинациям соединений, содержащих ингибиторы интегразы ВИЧ и другие терапевтические средства. Такие комбинации полезны в ингибировании репликации ВИЧ, предупреждении и/или лечении ВИЧ-инфекции и в лечении СПИДа и/или САК (СПИД-ассоциированного комплекса).
EA201690872A 2010-01-27 2011-01-24 Комбинация для лечения вич-инфекции EA032868B1 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US29858910P 2010-01-27 2010-01-27

Publications (3)

Publication Number Publication Date
EA201690872A2 true EA201690872A2 (ru) 2016-08-31
EA201690872A3 EA201690872A3 (ru) 2016-12-30
EA032868B1 EA032868B1 (ru) 2019-07-31

Family

ID=44319704

Family Applications (4)

Application Number Title Priority Date Filing Date
EA201690872A EA032868B1 (ru) 2010-01-27 2011-01-24 Комбинация для лечения вич-инфекции
EA201892277A EA037601B1 (ru) 2010-01-27 2011-01-24 Комбинация для лечения вич-инфекции
EA202190473A EA202190473A3 (ru) 2010-01-27 2011-01-24 Противовирусная терапия
EA201290583A EA025176B1 (ru) 2010-01-27 2011-01-24 Комбинация для лечения вич-инфекции

Family Applications After (3)

Application Number Title Priority Date Filing Date
EA201892277A EA037601B1 (ru) 2010-01-27 2011-01-24 Комбинация для лечения вич-инфекции
EA202190473A EA202190473A3 (ru) 2010-01-27 2011-01-24 Противовирусная терапия
EA201290583A EA025176B1 (ru) 2010-01-27 2011-01-24 Комбинация для лечения вич-инфекции

Country Status (45)

Country Link
US (13) US20120295898A1 (ru)
EP (6) EP3351249A1 (ru)
JP (8) JP2013518107A (ru)
KR (4) KR101883750B1 (ru)
CN (2) CN105311033B (ru)
AP (1) AP3551A (ru)
AU (1) AU2011209788C1 (ru)
BR (1) BR112012018670A2 (ru)
CA (4) CA3003988C (ru)
CL (1) CL2012002080A1 (ru)
CO (1) CO6602152A2 (ru)
CR (1) CR20120423A (ru)
CY (6) CY1116509T1 (ru)
DK (4) DK2932970T3 (ru)
DO (2) DOP2012000205A (ru)
EA (4) EA032868B1 (ru)
EC (1) ECSP12012106A (ru)
ES (4) ES2543066T3 (ru)
FI (2) FI3494972T3 (ru)
FR (2) FR18C1043I2 (ru)
HK (1) HK1250335A1 (ru)
HR (4) HRP20150770T1 (ru)
HU (6) HUE040554T2 (ru)
IL (5) IL221007A (ru)
LT (4) LT3127542T (ru)
LU (1) LUC00090I2 (ru)
MA (1) MA34002B1 (ru)
ME (2) ME02182B (ru)
MX (4) MX2012008774A (ru)
MY (2) MY188334A (ru)
NO (2) NO2932970T3 (ru)
NZ (4) NZ627824A (ru)
PE (2) PE20160180A1 (ru)
PH (3) PH12012501537A1 (ru)
PL (4) PL2531027T3 (ru)
PT (4) PT3127542T (ru)
RS (4) RS57728B1 (ru)
SG (3) SG10201707183TA (ru)
SI (4) SI2932970T1 (ru)
SM (4) SMT201800290T1 (ru)
TN (1) TN2012000376A1 (ru)
TR (1) TR201807704T4 (ru)
UA (1) UA105556C2 (ru)
WO (1) WO2011094150A1 (ru)
ZA (1) ZA201205586B (ru)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2932970T1 (en) 2010-01-27 2018-07-31 Viiv Healthcare Company Antiviral therapy
EP2911674A1 (en) 2012-10-23 2015-09-02 Cipla Limited Pharmaceutical antiretroviral composition
MY164352A (en) 2012-12-21 2017-12-15 Gilead Sciences Inc Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
EP2767272A1 (en) * 2013-02-18 2014-08-20 Ratiopharm GmbH Solid pharmaceutical dosage form of dolutegravir
US9480655B2 (en) 2013-02-18 2016-11-01 Ratiopharm Gmbh Solid pharmaceutical dosage form of dolutegravir
SI3019503T1 (sl) 2013-07-12 2017-11-30 Gilead Sciences, Inc. Policiklične karbamoilpiridonske spojine in njihova uporaba za zdravljenje HIV infekcij
NO2865735T3 (ru) 2013-07-12 2018-07-21
CN105744936B (zh) 2013-09-27 2019-07-30 默沙东公司 可用作hiv整合酶抑制剂的取代喹嗪衍生物
IN2014MU00916A (ru) 2014-03-20 2015-09-25 Cipla Ltd
EP3151920A4 (en) 2014-06-04 2017-12-27 Sanford-Burnham Medical Research Institute Use of inhibitor of apoptosis protein (iap) antagonists in hiv therapy
TW201613936A (en) 2014-06-20 2016-04-16 Gilead Sciences Inc Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
TWI744723B (zh) 2014-06-20 2021-11-01 美商基利科學股份有限公司 多環型胺甲醯基吡啶酮化合物之合成
NO2717902T3 (ru) 2014-06-20 2018-06-23
EP3177629B1 (en) 2014-07-29 2020-01-29 LEK Pharmaceuticals d.d. Novel hydrates of dolutegravir sodium
TWI695003B (zh) 2014-12-23 2020-06-01 美商基利科學股份有限公司 多環胺甲醯基吡啶酮化合物及其醫藥用途
SI3466490T1 (sl) 2015-04-02 2020-12-31 Gilead Sciences, Inc. Policiklične spojine karbamoilpiridona in njihova farmacevtska uporaba
WO2017029226A1 (en) 2015-08-14 2017-02-23 Sandoz Ag Solid pharmaceutical composition of abacavir, lamivudine, and efavirenz
WO2017205585A1 (en) * 2016-05-27 2017-11-30 Viiv Healthcare Company Combinations and uses treatments thereof
WO2018028841A1 (en) * 2016-08-12 2018-02-15 Sandoz Ag Solid pharmaceutical composition of abacavir, lamivudine, and efavirenz
WO2018042332A1 (en) * 2016-08-31 2018-03-08 Glaxosmithkline Intellectual Property (No.2) Limited Combinations and uses and treatments thereof
EP3655106A4 (en) * 2017-07-18 2021-04-21 VIIV Healthcare Company COMBINED INGREDIENTS THERAPY
CN117298114A (zh) 2017-07-21 2023-12-29 Viiv保健公司 用于治疗hib感染和aids的方案
JP2020528413A (ja) * 2017-07-21 2020-09-24 ヴィーブ ヘルスケア カンパニー Ｈｉｖ感染症及びａｉｄｓを治療するためのレジメン
JP2020536931A (ja) * 2017-10-13 2020-12-17 ヴィーブ ヘルスケア カンパニー 二層医薬錠剤製剤
BR112021018827A2 (pt) 2019-03-22 2021-11-23 Gilead Sciences Inc Compostos de carbamoilpiridona tricíclica em ponte e seu uso farmacêutico
BR112022013452A2 (pt) * 2020-01-09 2022-09-13 Univ Washington Combinações de agentes terapêuticos de ação prolongada e métodos das mesmas
MX2022009871A (es) 2020-02-24 2022-08-19 Gilead Sciences Inc Compuestos tetraciclicos para tratar la infeccion por el virus de la inmunodeficiencia humana (vih).
EP4321217A3 (en) 2021-01-19 2024-04-10 Gilead Sciences, Inc. Substituted pyridotriazine compounds and uses thereof
AU2023225805A1 (en) * 2022-02-28 2024-10-17 Jericho Sciences, Llc Methods for viral infections
TW202446773A (zh) 2022-04-06 2024-12-01 美商基利科學股份有限公司 橋聯三環胺甲醯基吡啶酮化合物及其用途

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7119202B1 (en) 1989-02-08 2006-10-10 Glaxo Wellcome Inc. Substituted-1,3-oxathiolanes and substituted-1,3-dioxolanes with antiviral properties
US5047407A (en) 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
GB8815265D0 (en) 1988-06-27 1988-08-03 Wellcome Found Therapeutic nucleosides
GB9009861D0 (en) 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
ZA923640B (en) 1991-05-21 1993-02-24 Iaf Biochem Int Processes for the diastereoselective synthesis of nucleosides
GB9111902D0 (en) 1991-06-03 1991-07-24 Glaxo Group Ltd Chemical compounds
GB9204015D0 (en) 1992-02-25 1992-04-08 Wellcome Found Therapeutic nucleosides
IL106507A (en) 1992-08-07 1997-11-20 Merck & Co Inc Pharmaceutical compositions containing benzoxazinones and some novel compounds of this type
US5519021A (en) 1992-08-07 1996-05-21 Merck & Co., Inc. Benzoxazinones as inhibitors of HIV reverse transcriptase
GB9402161D0 (en) 1994-02-04 1994-03-30 Wellcome Found Chloropyrimidine intermediates
IL113432A (en) 1994-04-23 2000-11-21 Glaxo Group Ltd Process for the diastereoselective synthesis of nucleoside analogues
UA49803C2 (ru) 1994-06-03 2002-10-15 Дж.Д. Сьорль Енд Ко Способ лечения ретровирусных инфекций
MY115461A (en) 1995-03-30 2003-06-30 Wellcome Found Synergistic combinations of zidovudine, 1592u89 and 3tc
US5914332A (en) 1995-12-13 1999-06-22 Abbott Laboratories Retroviral protease inhibiting compounds
US5849911A (en) 1996-04-22 1998-12-15 Novartis Finance Corporation Antivirally active heterocyclic azahexane derivatives
BR9709939A (pt) * 1996-06-25 1999-08-10 Glaxo Group Ltd Combinação formulação farmacêutica processo de tratamento de uma infecção por hiv em um animal infectado usos de éster tetraidro-3-furanila do ácido 3s[3r*(1r*,2s*)]-[-3-[[4-amino-fenil)sulfonil](2-metilprop ril)-amino]-2-hidroxi-1-fenilmetil)propil]-carbâmico de zidovudina e de (2r,cis)-4-amino-1-(2-hidroximetil-1,3-oxatiolan-5-il)-(1h)-pirimidin-2-ona e pacote para paciente
US5922695A (en) 1996-07-26 1999-07-13 Gilead Sciences, Inc. Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
US5965729A (en) 1997-02-05 1999-10-12 Merck & Co., Inc. Process for the crystallization of a reverse transcriptase inhibitor using an anti-solvent
GB9709945D0 (en) 1997-05-17 1997-07-09 Glaxo Group Ltd A novel salt
US5935946A (en) 1997-07-25 1999-08-10 Gilead Sciences, Inc. Nucleotide analog composition and synthesis method
GB9717928D0 (en) 1997-08-22 1997-10-29 Glaxo Group Ltd Process for the enatioselective hydrolysis of n-derivatised lactams
GB9721780D0 (en) 1997-10-14 1997-12-10 Glaxo Group Ltd Process for the synthesis of chloropurine intermediates
US6436989B1 (en) 1997-12-24 2002-08-20 Vertex Pharmaceuticals, Incorporated Prodrugs of aspartyl protease inhibitors
US6087383A (en) 1998-01-20 2000-07-11 Bristol-Myers Squibb Company Bisulfate salt of HIV protease inhibitor
GB9805898D0 (en) 1998-03-20 1998-05-13 Glaxo Group Ltd Process for the sythesis of hiv protease inhibitors
AU3366899A (en) 1998-03-27 1999-10-18 Regents Of The University Of California, The Novel hiv integrase inhibitors and hiv therapy based on drug combinations including integrase inhibitors
UA72207C2 (ru) 1998-04-07 2005-02-15 Брістол- Майєрс Сквібб Фарма Компані Фармацевтическая композиция эфавиренца в сочетании с ингредиентами, обеспечивающими распад таблеток, и способ изготовления быстрорастворимых таблеток и капсул эфавиренца
GB9809213D0 (en) * 1998-04-29 1998-07-01 Glaxo Group Ltd Pharmaceutical compositions
GB9815567D0 (en) 1998-07-18 1998-09-16 Glaxo Group Ltd Antiviral compound
PL211860B1 (pl) 2000-01-31 2012-07-31 Cook Biotech Inc Zespół zastawki stentu
PL216985B1 (pl) 2001-04-10 2014-06-30 Pfizer Pochodne pirazolu, kompozycja farmaceutyczna zawierająca je oraz ich zastosowania
US7638522B2 (en) * 2001-08-13 2009-12-29 Janssen Pharmaceutica N.V. Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile
MY169670A (en) 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
AR040242A1 (es) 2002-06-04 2005-03-23 Glaxo Group Ltd Composiciones farmaceuticas
MXPA04012754A (es) 2002-06-27 2005-03-23 Medivir Ab Interaccion sinergica de abacavir y alovudina.
ATE398455T1 (de) * 2003-01-14 2008-07-15 Gilead Sciences Inc Zusammensetzungen und verfahren zur antiviralen kombinationstherapie
TW200510425A (en) 2003-08-13 2005-03-16 Japan Tobacco Inc Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor
ES2433477T3 (es) 2004-02-11 2013-12-11 Glaxosmithkline Llc Inhibidores de integrasa de VIH
JP4285353B2 (ja) 2004-03-05 2009-06-24 清水建設株式会社 化学物質放散度評価方法
DK1742642T3 (da) * 2004-04-14 2009-02-16 Gilead Sciences Inc Phosphonatanaloge af HIV-integraseinhibitorforbindelser
EP2229945A1 (en) * 2004-05-21 2010-09-22 Japan Tobacco, Inc. Combinations comprising a 4-isoquinolone derivative and anti-HIV agents
US7176196B2 (en) 2004-05-28 2007-02-13 Bristol-Myers Squibb Company Bicyclic heterocycles as HIV integrase inhibitors
CN101022812A (zh) 2004-08-23 2007-08-22 特瓦制药工业有限公司 固体和晶体伊班膦酸钠及其制备方法
KR101284361B1 (ko) 2004-09-02 2013-07-15 얀센 파마슈티카 엔.브이. 4-((4-((4-(2-시아노에텐일)-2,6-디메틸페닐)아미노-2-피리미딘일)아미노)벤조니트릴의 하이드로클로라이드
DE602005023360D1 (de) 2004-09-17 2010-10-14 Idenix Pharmaceuticals Inc Phosphoindole als HIV-Inhibitoren
US7250421B2 (en) 2005-01-31 2007-07-31 University Of Georgia Research Foundation, Inc. Diketo acids with nucleobase scaffolds: anti-HIV replication inhibitors targeted at HIV integrase
EP1853604A4 (en) 2005-03-04 2010-02-24 Smithkline Beecham Corp CHEMICAL COMPOUNDS
CN101212903B (zh) * 2005-04-28 2013-07-24 史密丝克莱恩比彻姆公司 具有hiv整合酶抑制活性的多环氨基甲酰基吡啶酮衍生物
ES2892304T3 (es) * 2005-04-28 2022-02-03 Viiv Healthcare Co Derivado de carbamoilpiridona policíclico que tiene actividad inhibidora de la integrasa del VIH
CA2610029A1 (en) 2005-06-01 2006-12-07 Bioalliance Pharma Synergic combinations comprising a quinoline compound and other hiv infection therapeutic agents
EA018544B1 (ru) * 2005-12-30 2013-08-30 Джилид Сайэнс, Инк. Способ лечения ретровирусной инфекции
UA108605C2 (uk) * 2005-12-30 2015-05-25 Спосіб покращення фармакокінетики інгібіторів інтегрази віл
EA014914B1 (ru) * 2006-01-20 2011-02-28 Тиботек Фармасьютикалз Лтд. Долговременное лечение вич-инфекции
US20080039428A1 (en) 2006-06-29 2008-02-14 Panacos Pharmaceuticals, Inc. Antiretroviral combination therapy
EP2069303B1 (en) 2006-07-21 2016-03-30 Gilead Sciences, Inc. Antiviral protease inhibitors
US7960428B2 (en) 2006-09-29 2011-06-14 Idenix Pharmaceuticals, Inc. Enantiomerically pure phosphoindoles as HIV inhibitors
EA019893B1 (ru) 2007-02-23 2014-07-30 Джилид Сайэнс, Инк. Фармацевтическая композиция и способ лечения вич-инфекции
US20080241289A1 (en) 2007-02-23 2008-10-02 Auspex Pharmaceuticals, Inc. Preparation and utility of non-nucleoside reverse transcriptase inhibitors
KR20100041798A (ko) 2007-06-29 2010-04-22 한국화학연구원 신규 ｈｉｖ 역전사효소 억제제
ES2533863T3 (es) 2007-06-29 2015-04-15 Korea Research Institute Of Chemical Technology Inhibidores novedosos de la transcriptasa inversa de VIH
WO2009008989A1 (en) 2007-07-06 2009-01-15 Gilead Sciences, Inc. Modulators of pharmacokinetic properties of therapeutics
JP5701057B2 (ja) * 2007-07-12 2015-04-15 ヤンセン サイエンシズ アイルランド ユーシー （ｅ）４−［［４−［［４−（２−シアノエテニル）−２，６−ジメチルフェニル］アミノ］−２−ピリミジニル］アミノ］ベンゾニトリルの結晶形
WO2009058923A1 (en) 2007-10-31 2009-05-07 Smithkline Beecham Corporation Ccr5 antagonists as therapeutic agents
WO2009059243A1 (en) 2007-11-01 2009-05-07 The Uab Research Foundation Treating and preventing viral infections
US8108055B2 (en) 2007-12-28 2012-01-31 Larry Wong Method, system and apparatus for controlling an electrical device
MX2010007375A (es) * 2008-01-03 2010-09-30 Virochem Pharma Inc Nuevos derivados de lupano.
CN101977924A (zh) 2008-01-03 2011-02-16 Viro化学制药公司 新的c-21-酮基羽扇烷衍生物、其制备方法和应用
EP2231628B1 (en) 2008-01-04 2015-10-28 Gilead Sciences, Inc. Inhibitors of cytochrome p450
AU2009214779A1 (en) 2008-02-14 2009-08-20 Virochem Pharma Inc. Novel 17beta lupane derivatives
WO2009148600A2 (en) * 2008-06-06 2009-12-10 Concert Pharmaceuticals, Inc. Deuterated lysine-based compounds
SI2320908T1 (sl) * 2008-07-25 2014-05-30 Viiv Healthcare Company Predzdravila dolutegravirja
SG171731A1 (en) 2008-12-11 2011-07-28 Glaxosmithkline Llc Processes and intermediates for carbamoylpyridone hiv integrase inhibitors
JP5086478B2 (ja) * 2008-12-11 2012-11-28 塩野義製薬株式会社 カルバモイルピリドンｈｉｖインテグラーゼ阻害剤及びそれらの中間体の合成
SI2932970T1 (en) 2010-01-27 2018-07-31 Viiv Healthcare Company Antiviral therapy
GB201006038D0 (en) 2010-04-12 2010-05-26 Unilever Plc Improvements relating to antiviral compositions
EP2590971A4 (en) 2010-06-17 2014-12-10 Fuzians Biomedicals Inc COMPOUNDS USEFUL AS ANTIVIRAL AGENTS, COMPOSITIONS, AND METHODS OF USE
EP2694063A1 (en) 2011-04-01 2014-02-12 The Medicines Company Short -acting dihydropyridines (clevidipine) for use in reducing stroke damage

Also Published As

Publication number Publication date
SG10201707183TA (en) 2017-10-30
KR20160111536A (ko) 2016-09-26
CY1126771T1 (el) 2025-05-09
WO2011094150A1 (en) 2011-08-04
CO6602152A2 (es) 2013-01-18
DK2932970T3 (en) 2018-05-28
IL267658A (en) 2019-08-29
CY1120457T1 (el) 2019-07-10
ME02182B (me) 2015-10-20
CY2018029I2 (el) 2019-07-10
SI3494972T1 (sl) 2024-03-29
EP3494972A1 (en) 2019-06-12
CA2787691A1 (en) 2011-08-04
EA201690872A3 (ru) 2016-12-30
JP2018127473A (ja) 2018-08-16
KR101830715B1 (ko) 2018-04-04
DOP2012000205A (es) 2012-10-15
FR24C1024I1 (fr) 2024-07-26
IL257267B (en) 2019-08-29
RS65183B1 (sr) 2024-03-29
NZ627824A (en) 2016-02-26
US20210401850A1 (en) 2021-12-30
ME03058B (me) 2019-01-20
JP2016145204A (ja) 2016-08-12
NO2932970T3 (ru) 2018-08-18
ECSP12012106A (es) 2013-05-31
IL267658B (en) 2021-04-29
IL245182B (en) 2018-04-30
EP3351249A1 (en) 2018-07-25
KR20170078868A (ko) 2017-07-07
JP2013518107A (ja) 2013-05-20
SMT201800290T1 (it) 2018-07-17
EP3494972B1 (en) 2023-12-13
IL281959B (en) 2021-12-01
CN102791129B (zh) 2015-09-30
JP2019167371A (ja) 2019-10-03
PT3127542T (pt) 2018-11-26
PH12016500195A1 (en) 2016-12-05
DK2531027T3 (en) 2015-07-20
LTC2932970I2 (lt) 2022-04-25
DK3494972T3 (da) 2024-01-29
JP2021091705A (ja) 2021-06-17
SI2932970T1 (en) 2018-07-31
PE20121524A1 (es) 2012-12-03
EP3127542A1 (en) 2017-02-08
PH12016500195B1 (en) 2021-08-04
CA3003988C (en) 2020-01-07
IL257267A (en) 2018-03-29
PT2531027E (pt) 2015-09-16
NZ627827A (en) 2016-02-26
AU2011209788A1 (en) 2012-08-16
US20180200254A1 (en) 2018-07-19
JP2023085431A (ja) 2023-06-20
EA201892277A1 (ru) 2019-03-29
DOP2021000147A (es) 2022-01-16
US20150238496A1 (en) 2015-08-27
HRP20150770T1 (hr) 2015-08-28
NZ601319A (en) 2014-08-29
EP2531027A4 (en) 2013-07-03
NZ627826A (en) 2016-01-29
EA202190473A2 (ru) 2021-06-30
HUE037812T2 (hu) 2018-09-28
CL2012002080A1 (es) 2012-11-30
LUC00090I2 (ru) 2019-01-08
EP2531027A1 (en) 2012-12-12
CN105311033A (zh) 2016-02-10
EA032868B1 (ru) 2019-07-31
MX2012008774A (es) 2012-08-17
CA2967453C (en) 2018-07-17
PT3494972T (pt) 2024-02-12
PE20160180A1 (es) 2016-05-04
US20170079982A1 (en) 2017-03-23
CA3060290A1 (en) 2011-08-04
EA201290583A1 (ru) 2013-04-30
FIC20240016I1 (fi) 2024-05-31
SI3127542T1 (sl) 2018-11-30
CA2787691C (en) 2018-07-17
SMT201800594T1 (it) 2019-01-11
MY188334A (en) 2021-11-30
CY1116509T1 (el) 2017-03-15
MA34002B1 (fr) 2013-02-01
AP3551A (en) 2016-01-18
US20120295898A1 (en) 2012-11-22
CY1121040T1 (el) 2019-12-11
EA037601B1 (ru) 2021-04-20
FR18C1043I1 (ru) 2018-11-30
US20180098992A1 (en) 2018-04-12
MX367938B (es) 2019-09-12
MY202778A (en) 2024-05-21
HUE040554T2 (hu) 2019-03-28
EP3127542B1 (en) 2018-08-22
US20170119777A1 (en) 2017-05-04
SI2531027T1 (sl) 2015-08-31
HK1179522A1 (en) 2013-10-04
SMT201500177B (it) 2015-09-07
CA2967453A1 (en) 2011-08-04
RS57728B1 (sr) 2018-12-31
CY2024017I2 (el) 2025-05-09
CA3003988A1 (en) 2011-08-04
EA025176B1 (ru) 2016-11-30
HRP20180855T1 (hr) 2018-06-29
LT2932970T (lt) 2018-06-25
HRP20181531T1 (hr) 2018-11-16
LTPA2018013I1 (lt) 2018-11-12
HUE065569T2 (hu) 2024-06-28
KR20120128640A (ko) 2012-11-27
LT3494972T (lt) 2024-03-12
KR101883750B1 (ko) 2018-07-31
RS54123B1 (en) 2015-12-31
SG10201509476RA (en) 2015-12-30
EP2531027B1 (en) 2015-05-06
BR112012018670A2 (pt) 2018-02-06
ES2543066T3 (es) 2015-08-14
HUS1800042I1 (hu) 2018-11-28
PL3494972T3 (pl) 2024-05-27
PH12012501537A1 (en) 2018-02-07
KR101964923B1 (ko) 2019-04-02
IL221007A0 (en) 2012-09-24
ES2969969T3 (es) 2024-05-23
US20170216284A1 (en) 2017-08-03
EP4316599A3 (en) 2024-04-10
PL3127542T3 (pl) 2019-03-29
EP2932970B1 (en) 2018-03-21
ES2670811T3 (es) 2018-06-01
MX356891B (es) 2018-06-19
PT2932970T (pt) 2018-06-08
DK3127542T3 (en) 2018-11-12
CY2024017I1 (el) 2025-05-09
US11234985B2 (en) 2022-02-01
US20170281636A1 (en) 2017-10-05
TR201807704T4 (tr) 2018-06-21
HUS2400017I1 (hu) 2024-06-28
JP2017008087A (ja) 2017-01-12
HUE026849T2 (en) 2016-08-29
EA202190473A3 (ru) 2021-12-31
EP2932970A1 (en) 2015-10-21
PL2932970T3 (pl) 2018-08-31
TN2012000376A1 (en) 2014-01-30
MX367937B (es) 2019-09-12
LT3127542T (lt) 2018-11-26
US20160339033A1 (en) 2016-11-24
RS57323B1 (sr) 2018-08-31
SG182614A1 (en) 2012-08-30
UA105556C2 (ru) 2014-05-26
CN102791129A (zh) 2012-11-21
ES2688925T3 (es) 2018-11-07
FR24C1024I2 (fr) 2025-06-27
IL281959A (en) 2021-05-31
CY2018029I1 (el) 2019-07-10
EP4316599A2 (en) 2024-02-07
JP6268386B2 (ja) 2018-01-31
IL245182A0 (en) 2016-06-30
CR20120423A (es) 2012-11-22
KR20180078358A (ko) 2018-07-09
CA3060290C (en) 2022-07-12
FR18C1043I2 (fr) 2019-10-11
ZA201205586B (en) 2014-01-29
US20160199379A1 (en) 2016-07-14
SMT202400063T1 (it) 2024-03-13
AU2011209788B2 (en) 2014-02-06
US10426780B2 (en) 2019-10-01
HK1250335A1 (en) 2018-12-14
PH12018502489A1 (en) 2020-06-15
HK1209629A1 (en) 2016-04-08
AP2012006445A0 (en) 2012-08-31
AU2011209788C1 (en) 2014-08-28
FI3494972T3 (fi) 2024-03-01
US20200230147A1 (en) 2020-07-23
PL2531027T3 (pl) 2016-01-29
CN105311033B (zh) 2019-05-07
US20250017939A1 (en) 2025-01-16
HRP20240168T1 (hr) 2024-04-26
IL221007A (en) 2016-06-30
NO2018036I1 (no) 2018-10-15
JP2022071126A (ja) 2022-05-13

Similar Documents

Publication Publication Date Title
EA201690872A2 (ru) Противовирусная терапия
EA201291300A1 (ru) Производные нафт-2-илуксусной кислоты для лечения спида
EA202092456A3 (ru) Комбинированная терапия, включающая ингибитор mdm2 и один или более дополнительных фармацевтически активных агентов, для лечения различных видов рака
EA201590457A1 (ru) Сульфамоил-ариламиды и их применение в качестве лекарственных препаратов для лечения гепатита b
UA114006C2 (xx) Похідні 5-фенокси-3h-піримідин-4-ону і їхнє застосування як інгібіторів зворотної транскриптази віл
EA201391108A1 (ru) Лечение липодистрофии
EA201690687A1 (ru) Ингибиторы репликации вируса иммунодефицита
EA201590358A1 (ru) Ингибиторы репликации вируса иммунодефицита человека
EA201590703A1 (ru) Ингибиторы mek при лечении вирусных заболеваний
EA201590667A1 (ru) Ациламинопиримидиновые производные для лечения вирусных инфекций и других заболеваний
MX2023014492A (es) Compuestos utiles en la terapia para el vih.
MX343505B (es) Metodos y composiciones para inhibir la transmision del vih.
EA201591175A1 (ru) Трициклические соединения в качестве ингибиторов cftr
EA201590460A1 (ru) Способ и средство для лечения и профилактики заболеваний, вызываемых (+)рнк-содержащими вирусами
EA201290852A1 (ru) Комбинированная терапия, включающая антагонист ccr5, ингибитор протеазы вич-1 и фармакокинетический усилитель
EA201390925A1 (ru) Производные санглиферина и способы их получения
TW201613939A (en) Imidazopyridine macrocycles as inhibitors of human immunodeficiency virus replication

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): MD

ND4A Extension of term of a eurasian patent